DescriptionGilead Truvada for HIV PrEP - Blue Pills (48610083847).jpg
Truvada for PrEP, an HIV antiretroviral drug taken by HIV-negative persons in at-risk communities like people in relationships with partners who are HIV-positive or have an unknown status, to prevent an HIV infection. Taken daily, it can be about 99% effective in combination with safe sex practices. The medication is patented by the pharmaceutical company Gilead Sciences, and contains emtricitabine and tenofovir disoproxil fumarate, HIV nucleoside analog reverse transcriptase inhibitors. In other words, the drug works to stop the virus from making copies of itself in CD4+ T helper white blood cells, allowing the human immune system to eliminate the virus. The retail cost of the drug is about USD $2,000 per month, though insurance and co-pay assistance programs, some patients can obtain the medicine for free.
to share – to copy, distribute and transmit the work
to remix – to adapt the work
Under the following conditions:
attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the
same or compatible license as the original.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.
If the file has been modified from its original state, some details may not fully reflect the modified file.
Image title
Truvada for PrEP, an HIV antiretroviral drug taken by HIV-negative persons in at-risk communities like people in relationships with partners who are HIV-positive or have an unknown status, to prevent an HIV infection. Taken daily, it can be about 99% effective in combination with safe sex practices. The medication is patented by the pharmaceutical company Gilead Sciences, and contains emtricitabine and tenofovir disoproxil fumarate, HIV nucleoside analog reverse transcriptase inhibitors. In other words, the drug works to stop the virus from making copies of itself in CD4+ T helper white blood cells, allowing the human immune system to eliminate the virus. The retail cost of the drug is about USD $2,000 per month, though insurance and co-pay assistance programs, some patients can obtain the medicine for free.
DescriptionGilead Truvada for HIV PrEP - Blue Pills (48610083847).jpg
Truvada for PrEP, an HIV antiretroviral drug taken by HIV-negative persons in at-risk communities like people in relationships with partners who are HIV-positive or have an unknown status, to prevent an HIV infection. Taken daily, it can be about 99% effective in combination with safe sex practices. The medication is patented by the pharmaceutical company Gilead Sciences, and contains emtricitabine and tenofovir disoproxil fumarate, HIV nucleoside analog reverse transcriptase inhibitors. In other words, the drug works to stop the virus from making copies of itself in CD4+ T helper white blood cells, allowing the human immune system to eliminate the virus. The retail cost of the drug is about USD $2,000 per month, though insurance and co-pay assistance programs, some patients can obtain the medicine for free.
to share – to copy, distribute and transmit the work
to remix – to adapt the work
Under the following conditions:
attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the
same or compatible license as the original.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.
If the file has been modified from its original state, some details may not fully reflect the modified file.
Image title
Truvada for PrEP, an HIV antiretroviral drug taken by HIV-negative persons in at-risk communities like people in relationships with partners who are HIV-positive or have an unknown status, to prevent an HIV infection. Taken daily, it can be about 99% effective in combination with safe sex practices. The medication is patented by the pharmaceutical company Gilead Sciences, and contains emtricitabine and tenofovir disoproxil fumarate, HIV nucleoside analog reverse transcriptase inhibitors. In other words, the drug works to stop the virus from making copies of itself in CD4+ T helper white blood cells, allowing the human immune system to eliminate the virus. The retail cost of the drug is about USD $2,000 per month, though insurance and co-pay assistance programs, some patients can obtain the medicine for free.